HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase

被引:271
作者
Espeseth, AS
Felock, P
Wolfe, A
Witmer, M
Grobler, J
Anthony, N
Egbertson, M
Melamed, JY
Young, S
Hamill, T
Cole, JL
Hazuda, DJ
机构
[1] Merck Res Labs, Dept Antiviral Res, W Point, PA 19486 USA
[2] Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA
[3] Merck Res Labs, Dept Pharmacol, W Point, PA 19486 USA
关键词
D O I
10.1073/pnas.200139397
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Diketo acids such as L-731,988 are potent inhibitors of HIV-1 integrase that inhibit integration and viral replication in cells, These compounds exhibit the unique ability to inhibit the strand transfer activity of integrase in the absence of an effect on 3' end processing. To understand the reasons for this distinct inhibitory profile, we developed a scintillation proximity assay that permits analysis of radiolabeled inhibitor binding and integrase function. High-affinity binding of L-731,988 is shown to require the assembly of a specific complex on the HIV-1 long terminal repeat. The interaction of L-731,988 with the complex and the efficacy of L-731,988 in strand transfer can be abrogated by the interaction with target substrates. suggesting competition between the inhibitor and the target DNA. The L-731,988 binding site and that of the target substrate are thus distinct from that of the donor substrate and are defined by a conformation of integrase that is only adopted after assembly with the viral end. These results elucidate the basis for diketo acid inhibition of strand transfer and have implications for integrase-directed HIV-1 drug discovery efforts.
引用
收藏
页码:11244 / 11249
页数:6
相关论文
共 34 条
[21]   RESIDUES CRITICAL FOR RETROVIRAL INTEGRATIVE RECOMBINATION IN A REGION THAT IS HIGHLY CONSERVED AMONG RETROVIRAL RETROTRANSPOSON INTEGRASES AND BACTERIAL INSERTION-SEQUENCE TRANSPOSASES [J].
KULKOSKY, J ;
JONES, KS ;
KATZ, RA ;
MACK, JPG ;
SKALKA, AM .
MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (05) :2331-2338
[22]   REQUIREMENT OF ACTIVE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INTEGRASE ENZYME FOR PRODUCTIVE INFECTION OF HUMAN T-LYMPHOID CELLS [J].
LAFEMINA, RL ;
SCHNEIDER, CL ;
ROBBINS, HL ;
CALLAHAN, PL ;
LEGROW, K ;
ROTH, E ;
SCHLEIF, WA ;
EMINI, EA .
JOURNAL OF VIROLOGY, 1992, 66 (12) :7414-7419
[23]   Atomic resolution structures of the core domain of avian sarcoma virus integrase and its D64N mutant [J].
Lubkowski, J ;
Dauter, Z ;
Yang, F ;
Alexandratos, J ;
Merkel, G ;
Skalka, AM ;
Wlodawer, A .
BIOCHEMISTRY, 1999, 38 (41) :13512-13522
[24]  
LUTZKE RAP, 1994, NUCLEIC ACIDS RES, V22, P4125, DOI 10.1093/nar/22.20.4125
[25]   Inhibitors of human immunodeficiency virus integrase [J].
Pommier, Y ;
Neamati, N .
ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 :427-458
[26]  
SELNCIK HG, 1999, Patent No. 9962513
[27]   HUMAN-IMMUNODEFICIENCY-VIRUS INTEGRATION PROTEIN EXPRESSED IN ESCHERICHIA-COLI POSSESSES SELECTIVE DNA CLEAVING ACTIVITY [J].
SHERMAN, PA ;
FYFE, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (13) :5119-5123
[28]   Characterization of feline immunodeficiency virus integrase and analysis of functional domains [J].
Shibagaki, Y ;
Holmes, ML ;
Appa, RS ;
Chow, SA .
VIROLOGY, 1997, 230 (01) :1-10
[29]   COMPLEMENTATION BETWEEN HIV INTEGRASE PROTEINS MUTATED IN DIFFERENT DOMAINS [J].
VANGENT, DC ;
VINK, C ;
GROENEGER, AAMO ;
PLASTERK, RHA .
EMBO JOURNAL, 1993, 12 (08) :3261-3267
[30]   DNA-BINDING PROPERTIES OF THE INTEGRASE PROTEINS OF HUMAN IMMUNODEFICIENCY VIRUSES TYPE-1 AND TYPE-2 [J].
VANGENT, DC ;
ELGERSMA, Y ;
BOLK, MWJ ;
VINK, C ;
PLASTERK, RHA .
NUCLEIC ACIDS RESEARCH, 1991, 19 (14) :3821-3827